By Hendra Lukman 
Researchers have discovered that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for which patients chronic drug treatment could potentially be discontinued. This transcript, unique to CML, demonstrates superior sensitivity and accuracy compared to the current standard, real-time quantitative PCR (RT-qPCR), in detecting ultralow levels of residual leukemic disease. These groundbreaking findings are detailed in a novel study published in The Journal of Molecular Diagnostics, released by Elsevier.
A New Era in CML Management
Chronic myeloid leukemia (CML) is a slow-growing blood cancer that begins in the bone marrow. It is characterized by a specific genetic abnormality, the Philadelphia chromosome, which results from a reciprocal translocation between chromosomes 9 and 22. This translocation creates a fusion gene, BCR::ABL1, which encodes an abnormal tyrosine kinase protein. This protein drives the uncontrolled proliferation of white blood cells, leading to the development of CML.
For decades, the prognosis for CML patients was grim. However, the advent of targeted therapy, specifically tyrosine kinase inhibitors (TKIs), has transformed CML into a manageable chronic condition for most patients. TKIs work by inhibiting the activity of the BCR::ABL1 protein, thereby controlling the growth of leukemic cells. While TKIs have significantly improved survival rates and quality of life, they are typically taken for life. The prospect of discontinuing TKI treatment, known as treatment-free remission (TFR), has become a major goal for both patients and clinicians, offering the potential to reduce treatment-related side effects, improve long-term quality of life, and lower healthcare costs.
Achieving and accurately measuring deep molecular remission is paramount for TKI discontinuation. Deep molecular remission signifies that the leukemic cells have been reduced to undetectable or extremely low levels. The current standard for monitoring this remission is real-time quantitative polymerase chain reaction (RT-qPCR). However, RT-qPCR has limitations, particularly in detecting the vanishingly small amounts of residual disease that characterize deep remission. This is where the innovative digital PCR (dPCR) technology emerges as a potential game-changer.
Digital PCR: Unlocking Deeper Insights
The study, led by Peter E. Westerweel, MD, PhD, from the Department of Internal Medicine at Albert Schweitzer Hospital in Dordrecht, The Netherlands, investigated the utility of BCR::ABL1 digital PCR for assessing deep molecular remission. Digital PCR is a highly sensitive and precise nucleic acid detection technology that partitions a DNA sample into thousands to millions of individual reactions, or "droplets." Each droplet is then analyzed to determine whether it contains the target DNA sequence. This approach allows for absolute quantification of target molecules without the need for a standard curve, making it exceptionally accurate for detecting rare events.
"In our research, we show that digital PCR for BCR::ABL reaches a sufficiently high sensitivity in almost all (97%) samples of patients in deep molecular remission," stated Dr. Westerweel. "The molecular target was detected in two thirds of patients that were below the limit of detection of standard RT-qPCR technique. Digital PCR was therefore more sensitive and more accurate, allowing a reliable measurement to select CML patients in deep remission eligible for drug treatment discontinuation."
The study’s findings indicate that digital PCR can reliably quantify stable deep molecular remission of CML. This capability is crucial for identifying patients who are good candidates for attempting TKI discontinuation. The technology’s enhanced sensitivity means it can detect residual leukemic cells at levels far below what RT-qPCR can reliably measure, providing a more accurate picture of a patient’s true molecular status.
Methodology and Findings: A Nationwide Effort
The research was conducted as a nationwide prospective multicenter study, gathering samples from Dutch patients with CML for whom a TKI discontinuation attempt was being considered. This collaborative approach involved 31 medical centers across the Netherlands, ensuring a broad and representative patient population.
The data collection period spanned from July 2020 until May 2023. During this time, a total of 168 samples were collected from 136 patients. This comprehensive dataset allowed researchers to rigorously evaluate the performance of digital PCR against the established RT-qPCR method.
A key finding of the study was the remarkable sensitivity of digital PCR. The technology accurately quantified BCR::ABL1 levels around 0.0023% on the International Scale, a threshold considered clinically relevant for predicting treatment-free remission. The target sensitivity was set at MR5.0, meaning the assay could reliably detect one BCR::ABL1 transcript in a background of at least 100,000 normal copies of RNA. This level of precision was achieved in an impressive 97% of assessments.
Crucially, digital PCR was able to detect and quantify the BCR::ABL fusion gene in 68% of samples that fell below the limit of detection of standard RT-qPCR. This significant difference underscores the superior ability of dPCR to identify minimal residual disease (MRD). The ability to accurately measure these ultralow levels of residual disease is essential for making informed decisions about TKI discontinuation. If residual disease is still present, even at very low levels, discontinuing treatment could increase the risk of relapse.
Uncovering Transcript Type: A Novel Predictive Factor
Beyond its enhanced sensitivity for quantifying MRD, the study revealed another significant advantage of digital PCR: its ability to identify the specific type of BCR::ABL1 transcript a patient carries. BCR::ABL1 fusion transcripts are not uniform; they can arise from different breakpoints within the BCR gene, leading to variants such as e13a2 and e14a2. These transcript types have been previously associated with varying risks of molecular relapse after TKI discontinuation.
"Some patients have a so-called e13a2 transcript type, while others have an e14a2 transcript type," explained Dr. Westerweel. "We validated that the assay can be used to identify the transcript type in patients with detectable disease. This additional discovery is very relevant as we have previously shown that the transcript type is a risk factor for molecular relapse after drug discontinuation. Often, the transcript type is not known for patients and cannot be established using standard techniques once patients are in deep remission."
The researchers observed differences in the fluorescence levels of droplets generated by the digital PCR technique, correlating with different transcript types. Droplets with higher fluorescence indicated the presence of specific target transcript types. This discovery is highly valuable because identifying the transcript type is often challenging with conventional methods, especially when patients achieve deep molecular remission and the BCR::ABL1 transcript levels are extremely low. Knowing the transcript type allows clinicians to better assess the individual risk of relapse for each patient considering TKI discontinuation.
Implications for Clinical Practice and Future Directions
The implications of these findings for the management of CML are substantial. The study utilized an FDA-approved, commercially available BCR::ABL1 digital PCR assay, making its widespread clinical adoption feasible. This technological advancement promises to enhance patient care by enabling more precise monitoring of minimal residual disease and facilitating more accurate risk assessment for patients considering treatment-free remission.
The ability to reliably identify patients in stable, deep molecular remission with a lower risk profile for relapse could lead to a significant increase in the number of patients who can safely attempt TKI discontinuation. This, in turn, could improve the long-term health and well-being of a large CML patient population.
Broader Impact and Future Outlook:
The successful implementation of digital PCR for BCR::ABL1 monitoring could pave the way for similar advancements in other hematological malignancies that rely on MRD detection for treatment guidance. As personalized medicine continues to evolve, highly sensitive and accurate diagnostic tools are becoming indispensable for tailoring treatment strategies to individual patient needs.
The current study focused on the e13a2 and e14a2 transcript types, which are the most common. Further research may explore the utility of digital PCR in detecting and quantifying other less common BCR::ABL1 transcript variants, potentially expanding its diagnostic scope even further.
Moreover, the ongoing development of digital PCR technology itself, with increasing sensitivity and multiplexing capabilities, suggests that even more precise monitoring of residual disease will become possible in the future. This could lead to even more refined criteria for TKI discontinuation and potentially even novel therapeutic strategies aimed at eradicating the last remaining leukemic cells.
Dr. Westerweel concluded, "Digital PCR for BCR::ABL is a valuable and reliable tool to aid clinical decision making in CML." This sentiment is echoed by many in the hematology community, who recognize the potential of this technology to transform the landscape of CML management, offering renewed hope for a future where treatment-free remission is a more attainable reality for a greater number of patients. The study’s publication in The Journal of Molecular Diagnostics signifies a crucial step forward in harnessing the power of advanced molecular diagnostics for improved patient outcomes.